### **Dedication**

TO THE SOUL OF MY BELOVED FATHER ELHASSAN..

TO THE SOUL OF MY BELOVED SISTER SUSAN..

TO MY LOVELY MOTHER TYSEER..

TO MY GENTLE BROTHER KAREEM

TO MY SISTERS (NAHID , NAZOKA , ZOOBA , AFRAH

WHOM HAVE ALWAYS BEEN THE CANDLES OF MY LIFE

TO ALL OF MY AUNTS, UNCLES

TO ALL OF MY FRIENDS (HAFIZ, DR/KAREEM, OSAMA, MOAWYA, ESSAM, GAFFER, TALAL, AHMED, WAD AL AMIN, TAGWA,

TO EVERYONE SUPPORTED ME UNTIL I FINISHED THIS WORK LET ME EXPRESS DEEP THANKS TO ALL OF YOU

## Acknowledgement

First of all my prayers and thanks to our Almighty God Most Gracious and Most Merciful..who gave me the serenity, means of strength and patience to finish this work. I deeply indebted to my great and gentle supervisor **Dr/ Abd Allah abd al Kareem Osman** for his valuable, appreciated, help, support, and guidance during this study. I also respect and highly consider his patient assistance and invaluable advices.

My appreciation and thanks are extended to all of the **patients** with renal failure whom, without asking for any return showed and delivered great help to me without hesitation, and I hope to them quick recovery Inshallah, and to all medical staff in **Haemodialysis Unit** and **laboratory Unit** of Khartoum Teaching Hospital.

My special thanks to all teaching staff at Sudan University Of Science& Technology, Faculty of **Medical laboratory sciences.** 

#### **Abstract**

This study was hospital analytical case control, and it was conducted to determine haematological cells parameter among the adults Sudanese patients with chronic renal failure and whom on long term haemodialysis.

60 patients were informed about the study ,expected out come and agreement of participation were obtained , then the questionnaire was used to collect the information about patients age ,sex ,economical status ,frequency of dialysis ,status of associated iron and or erythropoietin therapy , and history of blood transfusion .

As well 4 ml of blood were taken from the patients pre dialysis in non vacuttanerK3 EDTA anticoagulant and it were used to evaluate cells blood counts, fully automated Sysmex kx21 were used to achieved the complete blood counts.

Computerized statistical package for social sciences version 11.5 were used to determine the samples size, and in subsequent data processing. The mean age of patients having chronic renal failure were 39 years, the results showed that 83.3 % were anemic and only 16.7 5 were normal, the mean of haemoglobin level, total erythrocyte counts, Packed cell volume, Mean cell volume, Mean cell volume, Mean cell haemoglobin, Mean cells haemoglobin concentration, total White blood cells counts, Platelets counts, and Main platelets volume were, 9.3783, 3.1617, 28.2467, 87.5967, 29.3467, 33.1400, 6.2250, 179.883, and 9.6683 Respectively.

For means of haemoglobin value , Red blood cells counts , and packed cells volume there were a higher level of significant variation in compared with control i.e. the significant were 0.000, 0.000, 0.000, for MCV there wasn't significant variation between the patients and control i.e. the significant were 0.457. for White blood cells there wasn't significant variation because the significant level were 0.308, and lastly for Platelets count and Mean Platelets volume there was a higher significant level 0.000, 0.000, 0.000, 0.000, Respectively. In conclusion the cells blood counts and its parameters are extremely Decreased as results of chronic renal failure.

#### ملخص الاطروحه

هذه دراسه تحليله تعتمد على المقارنه بين الحاله والمعيار المفترض ، تم اجرائها لتحديد مدي تاثر تعداد الخلايا الدمويه ومعاملاتها المختلفه ، لدي المرضى السودانيين البالغون المصابون بالفشل الكلوي المزمن بمستشفى الخرطوم التعليمي .

تم اخطار ٦٠ مريضا عن الدراسه واغراضها ،وبعد ذلك تم اخذ الموافقه .

بعد ذلك جمعت المعلومات من المرضي بواسطه الاستبيان عن الجنس ، العمر ، الحاله الاقتصاديه ، عدد مرات الغسيل في الاسبوع ، استخدام او عدم استخدم دوائي الاريثروبويتين و او الحديد ، و حصول او عدم حصول نقل دم ، في ال ٣ شهور الاخيره السابقه لاخذ العينه .

ايضا اخذت من المرضى ٤ ماليليتر من الدم قبل الغسيل مباشره في انبوبه اختبار تحتوي على مانع التجلط ( EDTA ) ، وقد استعملت لتحديد وتقييم تعداد الخلايا الدمويه ومعاملاتها .

تم استخدام جهاز ( Sysmex ) موديل ( 21 kx ) يعمل اوتوماتكيا لتعداد الخلايا الدمويه ومعاملاتها ، كما تم استخدام برنامج الحرم الاحصائيه للعلوم الجتماعيه نسخه رقم ١١.٥ لاجراء التحليل الحصائي .

وقد اظهرت نتائج التحليل الحصائى ان متوسط اعمار مرضى الفشل الكلوي المزمن هو ٣٩ سنه ، وايضا اظهرت النتائج ان ٨٣.٣ % من المرضي يعانون من فقر الدم والبقيه ١٦.٧ فقط هم اصحاء .

كما وجد ان متوسط تركيز الهيمقلوبين ، تعداد خلايا الدم الحمراء ، متوسط كتله الخلايا ، متوسط حجم الخلايا الحمراء ، متوسط هيموقلوبين الخليه الحمراء ، متوسط تعداد خلايا الدم البيضاء ، متوسط متوسط هيموقلوبين الخلايا الحمراء ، متوسط تعداد خلايا الدم البيضاء ، متوسط تعداد الصفائح الدمويه ، ومتوسط حجم الصفائح الدمويه هو 9.3783 ، 79.384 ، 79.883 ، 79.883 ، 79.883 ، 79.883 ، 6.2250 ، 33.1400 الاصحاء بنفس القيم

كما وجد ان متوسطات قيم الهيموقلوبين ، وتعداد خلايا الدم الحمراء ، ومتوسط كتله الخلايا ، تختلف اختلاف ذى دلاله احصائيه عاليه حيث وجد ان مستوى المعنويه يساوي ٠٠٠٠ ، ٠٠٠٠ علي التوالي ، وذلك عند المقارنه بمتوسطات الاشخاص الاصحاء لنفس القيم

اما بالنسبه لمتوسط حجم الخلايا ومتوسط تعداد خلايا الدم البيضاء فلم تكن هنالك اختلاف ذي دلاله احصائيه ومعنويه حيث كان مستوى المعنويه 0.308 ، 0.457 على التوالى ، وذلك عند المقارنه بمتوسطات الاشخاص الاصحاء لنفس القيم

كما وجد ان متوسط تعداد الصفائح الدمويه ومتوسط احجام الصفائح الدمويه يختلف اختلاف ذي دلاله احصائيه حيث كان مستوي المعنويه 0.000 ، 0.000 علي التوالي ، وذلك عند المقارنه بمتوسطات الاشخاص الاصحاء لنفس القيم ...

خلاصه : وجد ان تعداد ومعاملات الخلايا الدمويه يقل بشده بسبب الاصابه بالفشل الكلوي المزمن .

# List of abbreviation

AGM	aorta-gonads-mesonephros
CD()	Cluster of differentiation ()
CFU	Colony forming unit
GEMM	Granulocyte ,erythrocyte ,monocyte ,megakaryocyte
G-CSF	Granulocyte colony stimulating factor
GM-CSF	Granulocyte, monocyte colony stimulating factor
SDF	Stromal derived factor
SCF	Stem cells factor
IL()	Inter Luken ()
TNF	Tumor necrosis factor
Flt-L'	Felt ligands
G-CSF	Granulocyte colony stimulating factor
M-CSF	Monocyte colony stimulating factor
IFN-γ	Interferon gamma
TGF-β	Transforming growth factor beta
RNA	Ribo nucleic acid
EPO	Erythropoietin
SD	Standard deviation
MW	Molecular weight
RBC	Red blood cell
WBC	White blood cell
plt	platelet
CO2	Carbon di oxide
Hgb or Hb	haemoglobin
MCV	Mean cell volume
MCH	Mean cell haemoglobin
MCHC	Mean cells haemoglobin concentration
FL	Fimto liter
MPV	Mean platelets volume
CBC	Complete blood counts
RDW	Red cell distribution width
AKI	Acute kidney injury
ARF	Acute renal failure
CKI	Chronic kidney injury
CRD	Chronic renal disease

## List of table

NO	Name of tables	Page
1-1	site of haemopoiesis	2
1-2	General characteristics of myeloid and lymphoid	5
	growth factors.	
1-3	Haemopoietic growth factors.	5
1-4	Approximate Normal Blood Values	14
1-5	The complete blood count	16
4-1	Gender frequency	36
4-2	The mean and SD of the ages among the study	36
	population	
4-3	The ages groups among the study population	36
4-4	Relation between erythropoietin therapy and Hb level	37
	compared with mean of Hb (13.7 g/dl) and SD 1.2	
4-5	Iron therapy status among the study population	38
4-6	Relation between iron therapy and Hb level	38
4-7	Descriptive statistic of haematological parameter	40
	among the study population	
4-8	Statistical presentation of haematological parameter of	41
	patients compared with that of control	
4-9	Statistical test of hypothesis(T-test 95 % of confidence	42
	level and .05 of confidence interval)	

# List of figures

No	Name of figures	Page
4-1	The frequency of erythropoietin therapy.	37
4-2	The frequency of haemodialysis.	39
4-3	Economical status of study population	39

### **Contents**

## List of contents

Contents		Page		
	أيه			
Dedication	1	I		
Acknowle	dgment	II		
Abstract in	n English	III		
Abstract in	Abstract in Arabic			
List of ab	List of abbreviation			
List of	List of Tables			
List of fig	List of figures			
List of c	List of content			
	Chapter one introduction and			
	literature review			
1-1	Introduction	١		
1-2	Hematopoietic stem and progenitor cells.	3		
1_7_1	Bone marrow stroma	3		
1-2-2	Haemopoietic growth factor	4		
1-3-1	Erythropoiesis	6		
1-3-2	Control of erythropoiesis	7		
1-3-3	Tissue oxygen	8		
1-4-1	Erythropoietin	8		

1-4-2	Site and regulation of erythropoietin production	10
1-4-3	Indication for erythropoietin therapy	12
1-4-4	Cells and composition of peripheral blood	12
1-5-1	Erythrocyte (Red Blood Cell)	13
1-5-2	Leukocyte (White Blood Cell)	14
1-5-3	Leukocyte differential	15
1-5-4	Platelets(Thrombocytes)	15
1-5-5	The complete blood counts (CBC)	16
1-6-1	Erythrocytes counts	17
1-6-2	Leukocytes counts	17
1-6-3	Platelets counts	17
1-6-4	Kidneys function in homeostasis	18
1-6-5	Excretion of metabolic waste product ,foreign	18
	chemical ,drugs, and hormone metabolite.	
1-6-6	Regulation of water and electrolyte balance.	20
1-7-1	Regulation of arterial pressure	20
1-7-2	Regulation of acid base balance	20
1-7-3	Regulation of erythrocyte production	20
1-7-4	Regulation of 1.25 di hydroxyl vitamin D3	21
	production	
1-7-5	Glucose synthesis	20
1-7-6	Renal failure	21
1-7-7	Classification	21
1-8-1	Acute kidney injury	22
1-8-2	Chronic kidney disease	22
1-8-3	Acute-on-chronic renal failure	22
1-8-4	Symptoms of kidney diseases	23
1-8-5	Symptoms of kidney failure	23
1-8-6	Causes of chronic kidney disease	25
1-8-7	Investigations	26
1-8-8	Glomerular filtration rate	26
1-9-1	Use of term urea	27
1-9-2	Haemodialysis	27
1-9-3	Principle	27
	Chapter two	
	Objectives	
1-9-4	Justification	29
1-9-5	Hypothesis	29
2-1-1	General Objective	29
		1

2-1-2	Specific objectives	29
	Chapter Three	
	Methodology	
3-1-1	Study design	30
3-1-2	Study area	30
3-2-1	Study population	30
3-2-2	Sampling	30
3-3-1	Sample size	30
3-3-2	Tools of data collection	31
3-3-3	Inclusion criteria	31
3-4-1	Exclusion criteria	31
3-4-2	Data analysis	31
3-4-3	Approval consent	31
3-4-4	Safety assurance	31
3-5-1	Method of sample collection	32
3-5-2	Method of automated haematological analyzer	32
	system (CBC)	
3-5-3	Detection principle	33
3-5-4	Procedure	33
	Chapter Four	
	The Results	
4-1	General overview	34
4-2	Result presentation	34
	Chapter Five	
	Discussion, conclusion, recommendations	
5-1-1	Discussion	43
5-1-2	Conclusion	45
5-2-1	Recommendations	46
	Chapter six	
	References	
	References	48
	Appendix	